Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

5.260 -0.080 (-1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Aldeyra Therapeutics: Q4 Earnings Insights
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Aldeyra Therapeutics Q4 Earnings
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc
Via Business Wire
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Aldeyra Therapeutics Earnings Preview
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.... 
Via Benzinga
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today... 
Via Benzinga
Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 1.52% to 35,463.11 while the NASDAQ rose 2.10% to 15,295.45. The S&P also rose, gaining 1.55% to 4,638.74. The U.S. has... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The S&P also rose, gaining 0.80% to 4,605.08. The U.S. has the... 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
Stocks Set to Snap Selloff, Dow Eyes Triple-Digit Pop
The major benchmarks look set to snap their three-day losing streak today, as investors reassess their anxieties over the fast-spreading omicron variant. 
Via Talk Markets
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
10 Biggest Price Target Changes For Tuesday
B of A Securities lifted the price target on Micron Technology, Inc. (NASDAQ: 
Via Benzinga
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial... 
Via Benzinga
Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
From Aldeyra Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.